Takeda To Use Nycomed Ties To Speed Emerging-Nation Drug Launches
This article was originally published in PharmAsia News
Takeda Pharmaceutical plans to use its Nycomed acquisition and its sales network to launch drugs more quickly in emerging markets.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-one guidance documents have been posted on the tracker since its last update.
The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.